Fetal fibronectin for the prediction of preterm labor
Institute for Clinical Systems Improvement
Record ID 32003000548
English
Authors' objectives:
This review aims to assess the available evidence on the effectiveness of fetal fibronectin for the prediction of preterm labor.
Authors' recommendations:
With regard to the use of fetal fibronectin (fFN) for the prediction of preterm labor, the ICSI Technology Assessment Committee finds the following:
Symptomatic high-risk patients with a negative test result are highly unlikely to experience PTD within the next 7 days. The benefit of testing for fFN is a result of the high negative predictive value of the test. (Conclusion Grade I)
Testing for fFN is a safe procedure; the risks and limitations of the test are related to the false negative rate and the false positive rate.
The clinical importance of a positive test remains unclear.
The fFN test is not recommended as a screening test for asymptomatic patients, regardless of risk status.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.icsi.org/index.asp
Year Published:
2000
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Fibronectins
- Obstetric Labor, Premature
Contact
Organisation Name:
Institute for Clinical Systems Improvement
Contact Address:
8009 34th Avenue South, Suite 1200, Bloomington, MN, USA. Tel: +1 952 814 7060; Fax: +1 952 858 9675
Contact Name:
icsi.info@icsi.org
Contact Email:
icsi.info@icsi.org
Copyright:
Institute for Clinical Systems Improvement (ICSI)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.